Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.
Saved in:
| Title: | Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. |
|---|---|
| Authors: | Kinnunen KM; IXICO, London, United Kingdom., Mullin AP; Critical Path Institute, Tucson, AZ, United States.; Wave Life Sciences, Ltd., Cambridge, MA, United States., Pustina D; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Turner EC; Critical Path Institute, Tucson, AZ, United States., Burton J; Critical Path Institute, Tucson, AZ, United States., Gordon MF; Teva Pharmaceuticals, West Chester, PA, United States., Scahill RI; Huntington's Disease Research Centre, UCL Institute of Neurology, London, United Kingdom., Gantman EC; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Noble S; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Romero K; Critical Path Institute, Tucson, AZ, United States., Georgiou-Karistianis N; School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia., Schwarz AJ; Takeda Pharmaceuticals, Ltd., Cambridge, MA, United States. |
| Source: | Frontiers in neurology [Front Neurol] 2021 Oct 22; Vol. 12, pp. 712565. Date of Electronic Publication: 2021 Oct 22 (Print Publication: 2021). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34744964 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kinnunen+KM%22">Kinnunen KM</searchLink>; IXICO, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Mullin+AP%22">Mullin AP</searchLink>; Critical Path Institute, Tucson, AZ, United States.; Wave Life Sciences, Ltd., Cambridge, MA, United States.<br /><searchLink fieldCode="AU" term="%22Pustina+D%22">Pustina D</searchLink>; CHDI Management/CHDI Foundation, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Turner+EC%22">Turner EC</searchLink>; Critical Path Institute, Tucson, AZ, United States.<br /><searchLink fieldCode="AU" term="%22Burton+J%22">Burton J</searchLink>; Critical Path Institute, Tucson, AZ, United States.<br /><searchLink fieldCode="AU" term="%22Gordon+MF%22">Gordon MF</searchLink>; Teva Pharmaceuticals, West Chester, PA, United States.<br /><searchLink fieldCode="AU" term="%22Scahill+RI%22">Scahill RI</searchLink>; Huntington's Disease Research Centre, UCL Institute of Neurology, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gantman+EC%22">Gantman EC</searchLink>; CHDI Management/CHDI Foundation, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Noble+S%22">Noble S</searchLink>; CHDI Management/CHDI Foundation, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Romero+K%22">Romero K</searchLink>; Critical Path Institute, Tucson, AZ, United States.<br /><searchLink fieldCode="AU" term="%22Georgiou-Karistianis+N%22">Georgiou-Karistianis N</searchLink>; School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Schwarz+AJ%22">Schwarz AJ</searchLink>; Takeda Pharmaceuticals, Ltd., Cambridge, MA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101546899%22">Frontiers in neurology</searchLink> [Front Neurol] 2021 Oct 22; Vol. 12, pp. 712565. <i>Date of Electronic Publication: </i>2021 Oct 22 (<i>Print Publication: </i>2021). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation%22">Frontiers Research Foundation </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101546899 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2295 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642295%22">16642295 </searchLink><i>NLM ISO Abbreviation: </i>Front Neurol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34744964 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fneur.2021.712565 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 712565 Titles: – TitleFull: Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kinnunen KM – PersonEntity: Name: NameFull: Mullin AP – PersonEntity: Name: NameFull: Pustina D – PersonEntity: Name: NameFull: Turner EC – PersonEntity: Name: NameFull: Burton J – PersonEntity: Name: NameFull: Gordon MF – PersonEntity: Name: NameFull: Scahill RI – PersonEntity: Name: NameFull: Gantman EC – PersonEntity: Name: NameFull: Noble S – PersonEntity: Name: NameFull: Romero K – PersonEntity: Name: NameFull: Georgiou-Karistianis N – PersonEntity: Name: NameFull: Schwarz AJ IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 10 Text: 2021 Oct 22 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 1664-2295 Numbering: – Type: volume Value: 12 Titles: – TitleFull: Frontiers in neurology Type: main |
| ResultId | 1 |